MedTrace Logo

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)

NCT05928780 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 125

Last updated 2023-07-03

No results posted yet for this study

Summary

To explore the efficacy and safety of TROP2 in the treatment of ABC

Conditions

  • TNBC - Triple-Negative Breast Cancer

Interventions

DRUG

A1:SG with SHR3680

SG 10mg/kg d1, 8；SHR3680 240mg qd，3 weeks is a cycle

DRUG

A2:SG

SG 10mg/kg d1, 8

DRUG

B1:SG with SHR1210

SG 10mg/kg， d1, 8；SHR1210 200mg，d1，q3w；

DRUG

B2:SG

SG 10mg/kg， d1, 8

DRUG

C1:SG with SHR3162

SG 10mg/kg d1, 8；SHR3162，150mg，QD ，3 weeks is a cycle

DRUG

C2:SG

SG 10mg/kg d1, 8

DRUG

D1:SG with VEGFRI

SG 10mg/kg，d1, 8；BP102 15mg/kg，d1，3 weeks is a cycle

DRUG

D2:SG

SG 10mg/kg d1, 8

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-01
Primary Completion
2024-03-01
Completion
2025-09-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05928780 on ClinicalTrials.gov